US biopharma Sumitovant – a wholly owned subsidiary of Japan’s Sumitomo Pharma – has closed its purchase of the remaining equity in Myovant Sciences, taking full control of the Swiss clinical-stage biopharma for about $1.7 billion. Myovant will now be delisted from the New York Stock Exchange.
Valent BioSciences, a US-based subsidiary of Japan’s Sumitomo Chemical, has acquired FBSciences, a Tennessee-based company specializing in biostimulants. Financial terms were not disclosed.
Fertilizer giant Yara has entered into a Memorandum of Understanding (MoU) with Sumitomo Chemical under which the Norwegian group will examine the supply of clean ammonia to the Japanese firm’s production plants. Sumitomo would use the clean ammonia for producing petrochemicals and plastics and/or distributing energy out of its plants in Japan.
German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.
